Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 8 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

8(100.0%)

8Total

N/A(8)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06470425Not ApplicableCompleted

Optimizing Mental Health Management With AI-Guided (GenAIS TM) Dietary Supplementation

Role: collaborator

NCT06470412Not ApplicableCompleted

Personalized Management of Autoimmune Diseases With AI-Guided (GenAIS TM) Dietary Supplementation

Role: collaborator

NCT06188832Not ApplicableCompleted

Efficacy of Dietary Fiber Supplementation (Soloways) in Patients With Specific Genetic Polymorphisms

Role: collaborator

NCT06163443Not ApplicableCompleted

Evaluating the Impact of B Vitamin Supplementation (Soloways™) on Homocysteine and LDL-C Levels in Patients With MTHFR, MTR, and MTRR Polymorphisms.

Role: collaborator

NCT06154408Not ApplicableCompleted

Evaluating the Impact of Omega-3 Fatty Acid Supplementation (Soloways™) on Lipid Profiles in Adults With PPARG Polymorphisms

Role: collaborator

NCT06469658Not ApplicableCompleted

Personalized Management of Type 2 Diabetes Using AI-Guided (GenAIS TM) Dietary Supplementation

Role: collaborator

NCT06221696Not ApplicableCompleted

Preventing Weight Regain Post-Semaglutide Treatment With Active Fiber Supplement (Soloways)

Role: collaborator

NCT06215196Not ApplicableCompleted

Effectiveness and Safety of Semaglutide Combined With Dietary Fiber (Soloways) in Adults With Overweight or Obesity

Role: collaborator

All 8 trials loaded